AKT1 and cancer: Li et al found that LAPTM4B-35 motivates multidrug resistance of cancer cells by promoting drug efflux and anti-apoptosis by activating PI3K/AKT signaling [24], indicating that LAPTM4B-35 may be a new target of therapy.